Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Outline of Final Research Achievements |
We have revealed that the carbohydrate sulphotransferase CHST15 gene plays an important role in intestinal fibrosis in Crohn's disease, and developed a siRNA drug, STNM01, which selectively inhibits the expression of the gene, collaborating with the Stelic Institute of Regenerative Medicine, Tokyo. In this study, we have revealed that this new siRNA drug inhibited the progression of fibroblasts into myofibroblasts, and decresed the collagen production by fibroblasts, and that STNM01 could ameliorate chronic fibrosing DSS colitis. Additionally, we have revealed the overexpression of CHST15 in the colon of patients with Crohn's diseasae, suggesting that CHS15 could be a promissing target of the siRNA drug for the treatment of intestinal fibrosis in Crohn's disease.
|